ATS 2018 International Conference

Inhaled PI3Kδ Inhibitor Nemiralisib Improves Lung Function and Reduces Re-Exacerbations in Exacerbating Chronic Obstructive Pulmonary Disease (COPD) Patients (PII116678)

Location: PRE-FUNCTION 5-6

Session Type: Mini Symposium

Wednesday

May

11:00 AM

11:15 AM

Speaker(s)/Author(s)

Malcolm Begg

PhD
Glaxosmithkline

Jan De Backer

MSc, PhD
FLUIDDA;FLUIDDA NV

Cedric Van Holsbeke

PhD
FLUIDDA;FLUIDDA NV

Jon Robertson

PhD
GlaxoSmithKline

Maki Mizuma

PhD
Glaxosmithkline

Mickael Montembault

PhD
Glaxosmithkline

Yi Cui

PhD
Glaxosmithkline

Robert Wilson

PhD
GlaxoSmithKline

Anthony Cahn

MD
GlaxoSmithKline

J. Nicole Hamblin

PhD
Glaxosmithkline

Edith Hessel

PhD
Glaxosmithkline

Claudia Leemereise

MSc
Glaxosmithkline

Emily Jarvis

MSc
GlaxoSmithKline

View Abstract

Inhaled PI3Kδ Inhibitor Nemiralisib Improves Lung Function and Reduces Re-Exacerbations in Exacerbating Chronic Obstructive Pulmonary Disease (COPD) Patients (PII116678)

Parent Sessions

D12 - IMMUNOTHERAPY IN LUNG DISEASE...
05-23-2018 9:15 AM - 11:15 AM

Event

Inhaled PI3Kδ Inhibitor Nemiralisib Improves Lung Function and Reduces Re-Exacerbations in Exacerbating Chronic Obstructive Pulmonary Disease (COPD) Patients (PII116678)

Speaker(s)/Author(s)

Malcolm Begg

Jan De Backer

Cedric Van Holsbeke

Jon Robertson

Maki Mizuma

Mickael Montembault

Yi Cui

Robert Wilson

Anthony Cahn

J. Nicole Hamblin

Edith Hessel

Claudia Leemereise

Emily Jarvis

View Abstract

Inhaled PI3Kδ Inhibitor Nemiralisib Improves Lung Function and Reduces Re-Exacerbations in Exacerbating Chronic Obstructive Pulmonary Disease (COPD) Patients (PII116678)

Parent Sessions